High frequency of BRAF mutations in nevi

Pamela M. Pollock, Ursula L. Harper, Katherine S. Hansen, Laura M. Yudt, Mitchell Stark, Christiane M. Robbins, Tracy Y. Moses, Galen Hostetter, Urs Wagner, John Kakareka, Ghadi Salem, Tom Pohida, Peter Heenan, Paul Duray, Olli Kallioniemi, Nicholas K. Hayward, Jeffrey M. Trent, Paul S. Meltzer

Research output: Contribution to journalArticle

Abstract

To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.

Original languageEnglish (US)
Pages (from-to)19-20
Number of pages2
JournalNature Genetics
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Nevus
Mutation Rate
Melanoma
Mutation
Nevi and Melanomas
Amino Acid Substitution
Oncogenes
Sarcoma
Neoplasms
Carcinogenesis
Neoplasm Metastasis

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., ... Meltzer, P. S. (2003). High frequency of BRAF mutations in nevi. Nature Genetics, 33(1), 19-20. https://doi.org/10.1038/ng1054

High frequency of BRAF mutations in nevi. / Pollock, Pamela M.; Harper, Ursula L.; Hansen, Katherine S.; Yudt, Laura M.; Stark, Mitchell; Robbins, Christiane M.; Moses, Tracy Y.; Hostetter, Galen; Wagner, Urs; Kakareka, John; Salem, Ghadi; Pohida, Tom; Heenan, Peter; Duray, Paul; Kallioniemi, Olli; Hayward, Nicholas K.; Trent, Jeffrey M.; Meltzer, Paul S.

In: Nature Genetics, Vol. 33, No. 1, 01.01.2003, p. 19-20.

Research output: Contribution to journalArticle

Pollock, PM, Harper, UL, Hansen, KS, Yudt, LM, Stark, M, Robbins, CM, Moses, TY, Hostetter, G, Wagner, U, Kakareka, J, Salem, G, Pohida, T, Heenan, P, Duray, P, Kallioniemi, O, Hayward, NK, Trent, JM & Meltzer, PS 2003, 'High frequency of BRAF mutations in nevi', Nature Genetics, vol. 33, no. 1, pp. 19-20. https://doi.org/10.1038/ng1054
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. High frequency of BRAF mutations in nevi. Nature Genetics. 2003 Jan 1;33(1):19-20. https://doi.org/10.1038/ng1054
Pollock, Pamela M. ; Harper, Ursula L. ; Hansen, Katherine S. ; Yudt, Laura M. ; Stark, Mitchell ; Robbins, Christiane M. ; Moses, Tracy Y. ; Hostetter, Galen ; Wagner, Urs ; Kakareka, John ; Salem, Ghadi ; Pohida, Tom ; Heenan, Peter ; Duray, Paul ; Kallioniemi, Olli ; Hayward, Nicholas K. ; Trent, Jeffrey M. ; Meltzer, Paul S. / High frequency of BRAF mutations in nevi. In: Nature Genetics. 2003 ; Vol. 33, No. 1. pp. 19-20.
@article{85b707b8adbb42ba81cd3f525bcb98f7,
title = "High frequency of BRAF mutations in nevi",
abstract = "To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68{\%}) melanoma metastases, 4 of 5 (80{\%}) primary melanomas and, unexpectedly, in 63 of 77 (82{\%}) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.",
author = "Pollock, {Pamela M.} and Harper, {Ursula L.} and Hansen, {Katherine S.} and Yudt, {Laura M.} and Mitchell Stark and Robbins, {Christiane M.} and Moses, {Tracy Y.} and Galen Hostetter and Urs Wagner and John Kakareka and Ghadi Salem and Tom Pohida and Peter Heenan and Paul Duray and Olli Kallioniemi and Hayward, {Nicholas K.} and Trent, {Jeffrey M.} and Meltzer, {Paul S.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1038/ng1054",
language = "English (US)",
volume = "33",
pages = "19--20",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - High frequency of BRAF mutations in nevi

AU - Pollock, Pamela M.

AU - Harper, Ursula L.

AU - Hansen, Katherine S.

AU - Yudt, Laura M.

AU - Stark, Mitchell

AU - Robbins, Christiane M.

AU - Moses, Tracy Y.

AU - Hostetter, Galen

AU - Wagner, Urs

AU - Kakareka, John

AU - Salem, Ghadi

AU - Pohida, Tom

AU - Heenan, Peter

AU - Duray, Paul

AU - Kallioniemi, Olli

AU - Hayward, Nicholas K.

AU - Trent, Jeffrey M.

AU - Meltzer, Paul S.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.

AB - To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=0037228055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037228055&partnerID=8YFLogxK

U2 - 10.1038/ng1054

DO - 10.1038/ng1054

M3 - Article

VL - 33

SP - 19

EP - 20

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 1

ER -